Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	2011 - 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	2011 - 2021
Americas Revenue	412.12B	395.65B	Log In	Log In	Log In	Upgrade
Europe Revenue	226.53B	218.29B	Log In	Log In	Log In	Upgrade
China Revenue	85.52B	84.97B	Log In	Log In	Log In	Upgrade
Asia and Others Revenue	118.09B	120.05B	Log In	Log In	Log In	Upgrade
Japan Revenue	220.16B	217.21B	Log In	Log In	Log In	Upgrade

Revenue

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	2011 - 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	2011 - 2021
Cardiac and Vascular Company Revenue	640.15B	624.36B	Log In	Log In	Log In	Upgrade
Medical Care Solutions Company Revenue	212.60B	211.24B	Log In	Log In	Log In	Upgrade
Blood and Cell Technologies Company Revenue	209.35B	200.28B	Log In	Log In	Log In	Upgrade
Adjustments from Revenue	329.00M	298.00M	Log In	Log In	Log In	Upgrade

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	2011 - 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	2011 - 2021
Cardiac and Vascular Company Adjusted Operating Profit	164.82B	154.68B	Log In	Log In	Log In	Upgrade
Medical Care Solutions Company Adjusted Operating Profit	23.78B	22.99B	Log In	Log In	Log In	Upgrade
Blood and Cell Technologies Company Adjusted Operating Profit	28.91B	26.48B	Log In	Log In	Log In	Upgrade
Adjustments from Adjusted Operating Profit	-3.65B	-712.00M	Log In	Log In	Log In	Upgrade

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	2011 - 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	2011 - 2021
Cardiac and Vascular Company Production Result	620.90B	Log In	Log In	Log In	Upgrade
Medical Care Solutions Company Production Result	197.08B	Log In	Log In	Log In	Upgrade
Blood and Cell Technologies Company Production Result	205.67B	Log In	Log In	Log In	Upgrade
Total Production Result	1.02T	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.